Checkpoint Therapeutics Announces $10M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Portfolio Pulse from Benzinga Newsdesk
Checkpoint Therapeutics announced a $10 million registered direct offering priced at-the-market under Nasdaq rules.

May 23, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Checkpoint Therapeutics (CKPT) announced a $10 million registered direct offering priced at-the-market under Nasdaq rules, which may impact its stock price.
The announcement of a $10 million registered direct offering priced at-the-market may lead to dilution of existing shares, potentially causing a short-term negative impact on CKPT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100